GleamWall
中文EN

MAIA MAIA Biotechnology, Inc.

Pharmaceutical Preparations · NYSE · SEC CIK 1878313 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-12.4%
TTM EPS YoY36.5%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-341.5%
ROA-148.3%
ROIC (approx.)-296.5%
Asset turnover—

Leverage & solvency

Liabilities / assets33.6%
Debt / equity0.00x
Current ratio3.41x
Interest coverage—

Cash quality & payout

Operating cash flow / net income1.01x
Accruals ratio1.6%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue—$0
R&D expense$453,745$10.01M
SG&A expense$9.72M$6.95M
Operating income-$24.27M-$16.96M
Interest expense—$57
Pretax income-$22.39M-$23.25M
Income tax$2,000$2,000
Net income-$22.40M-$23.25M
EPS (basic)-0.70-1.05
EPS (diluted)-0.70-1.05
Weighted avg. shares (diluted)32.11M22.20M
Balance sheet
Cash & equivalents$0$0
Current assets$9.70M$10.15M
Total assets$9.70M$10.16M
Current liabilities$5.84M$3.83M
Total liabilities$7.33M$6.52M
Shareholders' equity$2.38M$3.63M
Shares outstanding38.62M26.16M
Cash flow statement
Operating cash flow-$18.84M-$15.70M
Financing cash flow$17.91M$18.18M
Stock-based compensation$2.63M$1.91M

Free plan shows the latest 2 periods; Pro shows all 5 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.